CONMED Corporation CNMD is well-positioned for growth on the back of rising adoption of its high-margin, differentiated ...

"Conmed to exit gastroenterology business" was originally created and published by Medical Device Network, a GlobalData owned ...

As of Friday, December 05, CONMED Corporation’s CNMD share price has dipped by 6.11%, which has investors questioning if this is right time to buy.

CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align ...

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. “My fellow directors and I are ...

CONMED Corporation CNMD delivered adjusted earnings per share (EPS) of $1.08 in the third quarter of 2025, up 2.9% year over year. The figure beat the Zacks Consensus Estimate by 2.9%. The adjustments ...

LARGO, Fla.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The ...

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Annual Meeting of Stockholders will be held as a virtual meeting on Wednesday, May 25, 2022, at 1:30 p.m. ET.

LARGO, Fla., November 05, 2025--CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2025.

W. L. Gore & Associates, Inc. ("Gore"), and ConMed Corporation ("ConMed") jointly announced today the upcoming transition of commercial support and distribution for the GORE® VIABIL® Biliary ...

CONMED Corporation has entered into an agreement to acquire New Haven-based medical technology company Biorez Inc. The deal is for cash consideration of $85 million at closing, with up to an ...

CONMED Corporation CNMD is well poised for growth in the coming quarters, courtesy of its broad product spectrum. The optimism, led by the solid recurring revenue base and potential in General Surgery ...